Form 4: Illumina Director Susan Siegel Receives Restricted Stock Unit Grant and Ownership Adjustment

Illumina, Inc. Director Susan E. Siegel was granted 3,780 restricted stock units, increasing her direct beneficial ownership to 14,463 shares, with an additional adjustment related to the Grail spin-out.

Summary

• Susan E. Siegel, a Director of Illumina, Inc. (ILMN), acquired 3,780 shares of common stock in the form of restricted stock units (RSUs) on May 21, 2025.
• The RSUs were granted at a price of $0, indicating they are part of compensation.
• Following this transaction, Ms. Siegel's direct beneficial ownership of Illumina common stock increased to 14,463 shares.
• The granted RSUs will vest 100% on the earlier of the one-year anniversary of the grant date or the date immediately preceding the company's annual meeting for the year following the grant, contingent on her continued service as a director.
• Additionally, Ms. Siegel's unvested RSUs were increased by 53 units due to an adjustment related to Illumina's spin-out of Grail, Inc., which was completed on June 24, 2024.

Sentiment

Score: 7

Explanation: The filing is a routine disclosure of director compensation, which is generally positive as it aligns director interests with shareholders. The adjustment for the Grail spin-out is a neutral, factual consequence of a prior corporate action.

Positives

• The grant of restricted stock units aligns the director's interests with long-term shareholder value.
• The increase in beneficial ownership by a director can be seen as a vote of confidence in the company's future.

Risks

• The vesting of the restricted stock units is contingent on Ms. Siegel's continued service as a director, meaning the shares could be forfeited if her service ceases before the vesting conditions are met.

Future Outlook

The vesting of the granted restricted stock units is contingent on the director's continued service, aligning future compensation with ongoing company performance and governance.

Management Comments

• The grant of restricted stock units to Director Susan E. Siegel is part of the company's compensation plan, designed to align director incentives with long-term shareholder value.

Industry Context

This filing is a routine disclosure of insider compensation, common across publicly traded companies, reflecting standard corporate governance practices where directors receive equity as part of their remuneration. The adjustment related to the Grail spin-out highlights the ongoing financial and structural impacts of significant corporate transactions within the biotechnology and life sciences sector.

Comparison to Industry Standards

• The grant of restricted stock units at a $0 price is a standard practice for director compensation in many industries, including biotechnology and healthcare, aiming to align director interests with shareholder value.
• Companies like Thermo Fisher Scientific (TMO) or Danaher Corporation (DHR) also utilize equity-based compensation for their board members.
• The specific vesting schedule (one-year anniversary or prior to next annual meeting) is also a common structure for director RSU grants, ensuring retention and ongoing commitment.
• The adjustment for the Grail spin-out is a specific event related to Illumina's corporate strategy, which is unique to its recent divestiture.

Stakeholder Impact

• Shareholders: The grant of equity to a director aligns their interests with long-term shareholder value, potentially fostering better governance and strategic decisions.

Next Steps

• Continued service of Susan E. Siegel as a director for the restricted stock units to vest.
• Vesting of the 3,780 restricted stock units on the earlier of the one-year anniversary of the grant date (May 21, 2026) or the date immediately preceding the company's annual meeting for the year following the grant.

Key Dates

Recommendation

Keywords

Illumina, ILMN, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Grant, Director Compensation, Stock Ownership, Grail Spin-out